Leukemia after staining with ethidium bromide and the hybridization is not obligatory. However, we have chosen it to confirm the results. 3. We agree with Dr Andersson about the necessity to change primers to detect the recently described new fusion genes. We try to do that actually in our laboratory as we hope to include additional frequent fusion genes in our multiplex strategy.
Introduction
Leukemia (2002) 16, 1576. doi:10.1038/sj.leu.2402666
Leukemia favors critical exchanges of views. We received a commentary from Dr David Rowe on a paper published in Leukemia 2001; 15: 57-61. As usual, the authors to whom the commentary was addressed were invited to reply. I am most indebted to Dr David Grimwade, who accepted to be the mediator in this exchange of interpretation of data. Not only did Dr Grimwade monitor this small Leukemia (2002) 16, 1576-1577. doi:10.1038/sj.leu.2402667 TO THE EDITOR Sarriera et al 1 recently reported on the incidence of cryptic AML1/ETO rearrangements found by polymerase chain reaction (PCR) in 104 cases of acute myeloid leukaemia (AML). We published a similar study of cytogenetically cryptic AML1/ETO fusion in a cohort of 412 patients 2 where we found an incidence of only 0.5%, substantially lower than the 7.7% reported by Sarriera et al. We were interested to account for this difference in incidence.
Diagnostic detection of AML1/ETO gene fusion by polymerase chain reaction
Of the eight cryptic cases they include, it appears that cytogenetic analysis was performed on only seven; the remaining case provided Since it therefore remains possible that this patient may actually have a conventional t(8;21) we contend that this case cannot be regarded as cryptic in the terms of their study and should be omitted. The incidence of AML1/ETO found by PCR alone should therefore be amended to 6.8% (seven cases in 103). One of the major conclusions from our study was the value of corroborating both cytogenetic and PCR data with a second detection method, principally fluorescent in situ hybridisation (FISH) using gene-specific probes. The value of this strategy appears to be recognised by Sarriera et al but the FISH approach they describe using whole chromosome paints combined with centromeric probes would not, in fact, detect a cytogenetically cryptic gene rearrangement. They did, however, corroborate PCR data by Western blot; this detected chimaeric AML1/ETO protein in three of the seven remaining patients positive for the fusion transcript by PCR but without a visible t(8;21). Given these data, it seems reasonable to regard the three patients with demonstrable fusion protein as having bona fide AML1/ETO rearrangement but, without confirmation of the PCR findings we suggest there is insufficient evidence to classify the other four cases as being rearranged and we contend that the incidence of cryptic AML1/ETO rearrangement from their data should be three cases in 103 or 2.9%. This is still higher than the incidence found in our data but can perhaps be explained by variation within their relatively small sample group.
The discrepancy between the incidence found by PCR alone and that which can be confirmed by other techniques is a matter of concern and highlights a potential flaw in the use of PCR as a diagnostic tool. The method used by Sarriera et al, although well controlled against false positivity by contamination or mispriming, is extremely sensitive and, since it involves a second round of amplification using nested primers, could result in the amplification of sub-clinical populations of cells, a possibility they acknowledge in their discussion. However, are such small populations of cells likely to be significant in the context of an acute leukaemia at diagnosis given that the large proportion of cells present in bone marrow will be from the major malignant clone? We suggest this is unlikely. Indeed, evidence already exists that small populations of cells with malignancy-related gene rearrangements are known to exist in tisssue from healthy donors; BCR/ABL, MLL/AF4 and BCL-2/IgH rearrangements have all been described, [3] [4] [5] but at levels as low as one cell in 10 6
. Such levels would be below detection by relatively insensitive but robust techniques such as cytogenetics, FISH, Southern or Western blotting and singleround PCR, but would be revealed by a two-round nested PCR. Additionally, studies on MLL/AF4 gene rearrangement in leukaemic patients 5 showed that they were detectable after one round of PCR only in patients with a cytogenetic rearrangement or a positive Southern blot. In cases where the only evidence for a gene rearrangement was a positive result after a second round of amplification the clinical course was unusual and suggested that the gene rearrangement was probably not a significant finding. It is also possible that haematopoietic tissue may contain populations of cells with AML1/ETO fusion that are not responsible for a malignant condition; indeed, the RT-PCR and survival data reported by Sarriera et al could be seen as evidence that it does. Our study suggests that a single round of PCR is sufficient at diagnosis -it is difficult to envisage a genuine malignant clone below that level of detection in an acute leukaemia at presentation. In cases where the initial round of PCR is negative, a second round of nested amplification is likely to be misleading and we sug-
Response to Drs Rowe and Bown
Leukemia ( The focus of our paper was to study the clinical relevance of the presence of PCR-detected t(8;21) translocation in AML patients with normal karyotype. Five of the 54 (9%) diploid patients had evidence for t(8;21) translocation by PCR. We included only patients with normal karyotype in our clinical correlation. The detection of t(8;21) in patients with normal karyotype was significantly higher than that detected in patients with abnormal karyotype (2 of 49).
We acknowledge the higher incidence of cryptic t(8;21) in our patients than in those of Rowe and Bown. This may reflect a difference in the patient population and/or a difference in the sensitivity between the two assays.
We agree that our FISH study was not sensitive enough because Leukemia gest that an alternative detection method should therefore be attempted. Unfortunately, Sarriera et al do not report which of their seven PCR cases were positive after the first round. Undeniably, nested PCR has a valuable role in the clinical management of malignancy but as a stand-alone diagnostic tool it is not ideal. The overall conclusion drawn from our data, which we feel is strengthened by the report by Sarriera et al, is that conventional cytogenetic analysis remains the most clinically important, single test on bone marrow at presentation. Supplementation of this analysis with a single round of RT-PCR for the fusion transcript and corroboration by genespecific FISH probes should provide the most clinically accurate range of genetic information available with current technology.
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